India, Feb. 10 -- Japan-based PHC Corporation has signed a Master Collaboration Agreement with CCRM (based in Canada) to work together on the development of primary T-cell expansion culture processes that will seek to accelerate the manufacturing of cell and gene therapy (CGT) products. This joint initiative will integrate LiCellGrow, PHC's cell expansion system under development, with CCRM's deep knowledge of regenerative medicine and biomanufacturing to establish new culture processes to improve cell culture efficiency and quality for CGTs.

The joint research with CCRM will allow PHC to analyse culture conditions using "LiCellGrow" to establish optimal culture processes for primary T-cells. The collaboration will seek to accelerate LiC...